The objectives of the current study were to evaluate differences in weight loss and improvement of obesity-related conditions between MBS patients with and without prior GLP-1 RA treatment up to 36 months after surgery, as well as to explore reasons for transitioning from GLP-1 therapy to surgery. The gene discussed is GLP1R; the disease is obesity disorder.